ADC Therapeutics SA - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance

More Details of ADC Therapeutics SA Company

ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.

ADC Therapeutics SA Info



Ticker SymbolADCT

Company nameADC Therapeutics SA

IPO dateMay 15, 2020

CEOMr. Ameet Mallik

Number of employees263

Security typeOrdinary Share

Fiscal year-endMay 15

AddressBiopole

CityEPALINGES

Stock exchangeNYSE Consolidated

CountrySwitzerland

Postal code1066

Phone41216530200

Websitehttps://adctherapeutics.com/

Ticker SymbolADCT

IPO dateMay 15, 2020

CEOMr. Ameet Mallik

Company Executives of ADC Therapeutics SA



Name

Name/Position

Position

Shareholding

Change

Mr. Ron R. Squarer

Non-Executive Chairman of the Board

1.58M

+1.60%

Mr. Ameet Mallik

Chief Executive Officer, Director

1.55M

-1.70%

Mr. Mohamed Zaki, M.D., Ph.D.

Chief Medical Officer

642.33K

+50.70%

Mr. Jose (Pepe) Carmona

Chief Financial Officer

404.81K

+0.52%

Mr. Peter J. Graham

Chief Legal and Compliance Officer and Secretary

361.04K

-11.63%

Dr. Peter Hug, Ph.D.

Non-Executive Vice Chairman of the Board, Lead Independent Director

180.50K

+26.54%

Ms. Viviane Monges

Non-Executive Independent Director

134.98K

+38.35%

Dr. Victor Sandor, M.D.

Non-Executive Independent Director

99.40K

+38.06%

Mr. Robert W. (Bob) Azelby

Non-Executive Independent Director

55.26K

+98.35%

Mr. Timothy P. (Tim) Coughlin, CPA

Director

40.00K

--

Name

Name/Position

Position

Shareholding

Change

Mr. Ron R. Squarer

Non-Executive Chairman of the Board

1.58M

+1.60%

Mr. Ameet Mallik

Chief Executive Officer, Director

1.55M

-1.70%

Mr. Mohamed Zaki, M.D., Ph.D.

Chief Medical Officer

642.33K

+50.70%

Mr. Jose (Pepe) Carmona

Chief Financial Officer

404.81K

+0.52%

Mr. Peter J. Graham

Chief Legal and Compliance Officer and Secretary

361.04K

-11.63%

Dr. Peter Hug, Ph.D.

Non-Executive Vice Chairman of the Board, Lead Independent Director

180.50K

+26.54%

Revenue Breakdown

No Data

No Data

By Business

By Region

No Data

Shareholding Stats

Updated: Thu, Oct 2

Shareholders

Shareholder Types

Shareholders

Proportion

Redmile Group, LLC

13.93%

Prosight Capital

9.30%

HPWH TH AG

7.71%

Point72 Asset Management, L.P.

6.90%

OrbiMed Advisors, LLC

5.25%

Other

56.91%

Shareholders

Proportion

Redmile Group, LLC

13.93%

Prosight Capital

9.30%

HPWH TH AG

7.71%

Point72 Asset Management, L.P.

6.90%

OrbiMed Advisors, LLC

5.25%

Other

56.91%

Shareholder Types

Shareholders

Proportion

Investment Advisor/Hedge Fund

22.78%

Hedge Fund

19.46%

Corporation

9.69%

Investment Advisor

9.20%

Research Firm

6.61%

Individual Investor

5.81%

Private Equity

5.25%

Bank and Trust

0.86%

Insurance Company

0.02%

Other

20.31%

Institutional Shareholding



Updated: Wed, Oct 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q3

184

72.23M

64.20%

+2.08M

2025Q2

209

87.64M

88.37%

-14.63M

2025Q1

217

80.51M

81.56%

-23.93M

2024Q4

219

81.03M

83.80%

-19.29M

2024Q3

223

79.78M

82.57%

-21.86M

2024Q2

215

76.61M

81.35%

-7.96M

2024Q1

177

59.13M

71.30%

-27.56M

2023Q4

169

58.32M

71.49%

-25.86M

2023Q3

180

68.48M

85.02%

-18.63M

2023Q2

182

74.11M

92.00%

-12.88M

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

Redmile Group, LLC

15.67M

13.93%

--

Jun 30, 2025

Prosight Capital

10.47M

9.3%

+924.77K

+9.69%

Jun 30, 2025

HPWH TH AG

8.67M

7.71%

-1.12M

-11.42%

May 15, 2025

Point72 Asset Management, L.P.

7.76M

6.9%

+7.76M

--

Jun 30, 2025

OrbiMed Advisors, LLC

5.91M

5.25%

-61.10K

-1.02%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

4.06M

3.6%

-442.92K

-9.85%

Jun 30, 2025

Oaktree Capital Management, L.P.

4.02M

3.57%

+4.02M

--

Apr 25, 2024

Morgan Stanley & Co. LLC

2.99M

2.66%

+33.76K

+1.14%

Jun 30, 2025

Heights Capital Management, Inc.

2.83M

2.52%

+2.83M

--

Jun 30, 2025

Nantahala Capital Management, LLC

2.27M

2.01%

+2.27M

--

Jun 30, 2025

Related ETFs



Updated: 7 hours ago

Name

Proportion

iShares Micro-Cap ETF

0.06%

SPDR S&P International Small Cap ETF

0.04%

iShares Biotechnology ETF

0.03%

iShares Russell 2000 Growth ETF

0.02%

ProShares UltraPro Russell2000

0.01%

ProShares Hedge Replication ETF

0.01%

Proshares Ultra Russell 2000

0.01%

Global X Russell 2000 ETF

0.01%

iShares Russell 2000 ETF

0.01%

Fidelity Enhanced Small Cap ETF

0%

iShares Micro-Cap ETF

Proportion0.06%

SPDR S&P International Small Cap ETF

Proportion0.04%

iShares Biotechnology ETF

Proportion0.03%

iShares Russell 2000 Growth ETF

Proportion0.02%

ProShares UltraPro Russell2000

Proportion0.01%

ProShares Hedge Replication ETF

Proportion0.01%

Proshares Ultra Russell 2000

Proportion0.01%

Global X Russell 2000 ETF

Proportion0.01%

iShares Russell 2000 ETF

Proportion0.01%

Fidelity Enhanced Small Cap ETF

Proportion0%

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Split



Date

Type

Ratio

No Data

Date

Type

Ratio

No Data